OncoMed Pharmaceuticals, Inc.

Optomed reports Q1 2026 operating loss of 1.37 million euros, revenue decline

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

Capstone

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

MetaVia

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

OMED

CS精准医

Okami Medical has announced the enrollment of the first patient in the ALPHA Registry, which evaluates the safety and effectiveness of the LOBO™ Vascular Occlusion System for various peripheral vascular conditions. The LOBO device aims to provide controlled occlusion of peripheral vessels efficiently. The registry will enroll up to 500 patients across 30 sites, contributing to clinical evidence supporting the LOBO system's use in embolization procedures. This initiative is part of Okami's strategy to enhance patient care through innovative medical solutions.

prnewswire

16:06 ETOkami Medical Announces First Patient Enrolled in ALPHA Registry

Optiscan has submitted a regulatory dossier to the FDA for its InSpecta digital imaging device aimed at the US veterinary market. This submission is a significant step towards regulatory approval, enhancing the company's engagement with veterinary customers. The US veterinary market, valued at approximately $11.92 billion in 2022, is projected to grow at an 8.7% annual rate through 2030. InSpecta aims to provide real-time, non-invasive imaging for complex animal health conditions, potentially transforming veterinary care.

Small Caps

Health Care Select Sector SPDR

QT Imaging

SPDR S&P Health

SPDR S&P Health Equip

iShares US Healthcare Providers

VG Health

iShares Global Healthcare

ALPS Medical Breakthrough

Beamr Imaging

iShares US Medical Devices

Optiscan Submits FDA Dossier for Inspecta Imaging Device Targeting Lucrative US Veterinary Market

Alpha has been chosen as the inaugural Medspa platform partner due to their dedication to innovation, education, and overcoming obstacles. This partnership highlights Alpha's exceptional qualities and positions them as a key player in the industry.

Unusual Whales

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

Alopexx

VanEck Biotech ETF

Aesthetic Medical International Holdings Group Limited

Proshares Ultra Nasdaq Biotech

Ocular Therap

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Obagi Medical and Alpha Aesthetic Partners collaborate in ALOHA Program with Obagi MagIQ, the first Medspa partner chosen for innovation and education.

003008

On January 21st local time, medical artificial intelligence startup OpenEvidence announced the completion of a $250 million Series D financing, with the company's valuation reaching $12 billion. This round of financing was led by Thrive Capital and DST Global, with a total financing amount close to $700 million. (Jiemian)

36Kr

KETOP

Geratherm Medical AG

Medical AI startup OpenEvidence raises $250 million, with a valuation of $12 billion

OpenEvidence, a medical AI startup, has achieved a $12 billion valuation following a $250 million funding round led by Thrive Capital and DST. The company, known as "ChatGPT for doctors," has seen rapid adoption, with its AI tool used by 40% of U.S. doctors and generating over $100 million in annual revenue. Founded in 2022 by Daniel Nadler, OpenEvidence primarily relies on advertising for revenue, targeting small clinics. Despite competition from larger AI firms, Nadler believes OpenEvidence's real-world usage gives it a competitive edge.

Tip Ranks

Medical AI Startup OpenEvidence Reaches $12 Billion on Rapid Doctor Adoption

OncoMed Pharmaceuticals, Inc.(OMED.US)

16:06 ETOkami Medical Announces First Patient Enrolled in ALPHA Registry

Optiscan Submits FDA Dossier for Inspecta Imaging Device Targeting Lucrative US Veterinary Market

Obagi Medical and Alpha Aesthetic Partners collaborate in ALOHA Program with Obagi MagIQ, the first Medspa partner chosen for innovation and education.

Medical AI startup OpenEvidence raises $250 million, with a valuation of $12 billion

Medical AI Startup OpenEvidence Reaches $12 Billion on Rapid Doctor Adoption